{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Poorly+Differentiated+Adenocarcinoma", "query": { "condition": "Poorly Differentiated Adenocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Poorly+Differentiated+Adenocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T10:56:18.585Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 37, "start_date": "2001-05", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161187" }, { "nct_id": "NCT02345460", "title": "Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Poorly Differentiated Malignant Neoplasm", "Resectable Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer", "Undifferentiated Pancreatic Carcinoma" ], "interventions": [ { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2015-09", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2018-07-13", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02345460" }, { "nct_id": "NCT00897793", "title": "Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Lung Cancer", "Prostate Cancer" ], "interventions": [ { "name": "venipuncture", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-01", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897793" }, { "nct_id": "NCT00019019", "title": "Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Breast Cancer", "Kidney Cancer", "Lung Cancer", "Lymphoma", "Melanoma (Skin)", "Ovarian Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboxyamidotriazole", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "1994-10", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019019" }, { "nct_id": "NCT00049023", "title": "Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Neuroblastoma", "Pheochromocytoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "90Y-DOTA-tyr3-OCTREOTIDE", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "O'Dorisio, M S", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 27, "start_date": "2002-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2016-06-21", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049023" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT00006368", "title": "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Breast Cancer", "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Lung Cancer", "Lymphoma", "Melanoma (Skin)", "Neoplastic Syndrome" ], "interventions": [ { "name": "yttrium Y 90-edotreotide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1998-01", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-05-01", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006368" }, { "nct_id": "NCT07080242", "title": "Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer Metastatic or Locally Advanced", "Neuroendocrine Cancer", "Metastatic Neuroendocrine Prostate Cancer", "Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma", "Metastatic Advanced Merkel Cell Carcinoma", "Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung", "Locally Advanced Extrapulmonary Neuroendocrine Carcinoma", "Locally Advanced Neuroendocrine Prostate Cancer", "Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine", "Locally Advanced Merkel Cell Carcinoma", "Metastatic Large Cell Neuroendocrine Carcinoma of the Lung" ], "interventions": [ { "name": "BL-M14D1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SystImmune Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-04-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 20, "location_summary": "Huntsville, Alabama • Los Angeles, California • San Francisco, California + 14 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07080242" }, { "nct_id": "NCT04759911", "title": "Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Thyroid Gland Neoplasm", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Thyroid Gland Anaplastic Carcinoma", "Thyroid Gland Medullary Carcinoma", "Thyroid Gland Papillary Carcinoma", "Thyroid Gland Squamous Cell Carcinoma" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 30, "start_date": "2021-02-26", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Houston, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04759911" }, { "nct_id": "NCT02973997", "title": "Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Columnar Cell Variant Thyroid Gland Papillary Carcinoma", "Follicular Variant Thyroid Gland Papillary Carcinoma", "Metastatic Thyroid Gland Follicular Carcinoma", "Metastatic Thyroid Gland Papillary Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Follicular Carcinoma", "Recurrent Thyroid Gland Papillary Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Tall Cell Variant Thyroid Gland Papillary Carcinoma", "Thyroid Gland Hurthle Cell Carcinoma", "Unresectable Differentiated Thyroid Gland Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Lenvatinib Mesylate", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2018-02-07", "completion_date": "2023-10-08", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-07-22T10:56:18.585Z", "location_count": 7, "location_summary": "Torrance, California • Aurora, Colorado • Boston, Massachusetts + 4 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02973997" } ] }